A detailed history of Los Angeles Capital Management LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 5,124 shares of MDGL stock, worth $2.71 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,124
Previous 5,149 0.49%
Holding current value
$2.71 Million
Previous $1.56 Million 50.83%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 20, 2025

SELL
$287.52 - $458.66 $7,188 - $11,466
-25 Reduced 0.49%
5,124 $2.35 Million
Q2 2025

Aug 06, 2025

BUY
$267.56 - $340.8 $683,080 - $870,062
2,553 Added 98.34%
5,149 $1.56 Million
Q1 2025

May 05, 2025

SELL
$272.79 - $355.88 $42,555 - $55,517
-156 Reduced 5.67%
2,596 $859,000
Q4 2024

Feb 04, 2025

BUY
$202.45 - $354.85 $557,142 - $976,547
2,752 New
2,752 $849,000
Q1 2023

May 04, 2023

BUY
$231.06 - $307.08 $237,760 - $315,985
1,029 New
1,029 $249,000
Q2 2021

Aug 05, 2021

SELL
$97.2 - $137.59 $608,472 - $861,313
-6,260 Closed
0 $0
Q1 2021

May 05, 2021

SELL
$108.54 - $125.2 $564,625 - $651,290
-5,202 Reduced 45.38%
6,260 $732,000
Q4 2020

Feb 04, 2021

BUY
$110.06 - $133.7 $13,757 - $16,712
125 Added 1.1%
11,462 $1.27 Million
Q3 2020

Nov 02, 2020

SELL
$99.78 - $124.21 $165,634 - $206,188
-1,660 Reduced 12.77%
11,337 $1.35 Million
Q2 2020

Aug 05, 2020

BUY
$60.13 - $125.71 $15,333 - $32,056
255 Added 2.0%
12,997 $1.47 Million
Q1 2020

May 04, 2020

BUY
$66.76 - $93.49 $850,655 - $1.19 Million
12,742 New
12,742 $851,000
Q3 2019

Nov 07, 2019

SELL
$84.4 - $106.53 $173,273 - $218,706
-2,053 Closed
0 $0
Q2 2019

Jul 29, 2019

BUY
$91.13 - $142.5 $187,089 - $292,552
2,053 New
2,053 $215,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $9.05B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.